Tealwood Asset Management Inc. raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,150 shares of the medical research company’s stock after acquiring an additional 585 shares during the period. Tealwood Asset Management Inc.’s holdings in Thermo Fisher Scientific were worth $2,117,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also recently made changes to their positions in TMO. Capital Research Global Investors raised its holdings in shares of Thermo Fisher Scientific by 29.8% in the second quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock worth $3,019,185,000 after buying an additional 3,973,136 shares during the last quarter. Janus Henderson Group PLC raised its holdings in shares of Thermo Fisher Scientific by 2,058.1% in the second quarter. Janus Henderson Group PLC now owns 2,342,046 shares of the medical research company’s stock worth $408,620,000 after buying an additional 2,233,522 shares during the last quarter. Veritas Asset Management LLP raised its holdings in shares of Thermo Fisher Scientific by 112.4% in the second quarter. Veritas Asset Management LLP now owns 2,430,759 shares of the medical research company’s stock worth $424,095,000 after buying an additional 1,286,259 shares during the last quarter. Meritage Group LP purchased a new position in shares of Thermo Fisher Scientific in the third quarter worth $201,383,000. Finally, Capital World Investors raised its holdings in shares of Thermo Fisher Scientific by 6.1% in the second quarter. Capital World Investors now owns 11,759,734 shares of the medical research company’s stock worth $2,051,721,000 after buying an additional 671,637 shares during the last quarter. Institutional investors own 86.25% of the company’s stock.
Shares of Thermo Fisher Scientific Inc. (TMO) traded up $1.10 during trading on Friday, hitting $213.51. 1,418,994 shares of the company traded hands, compared to its average volume of 1,577,492. The company has a current ratio of 1.26, a quick ratio of 0.81 and a debt-to-equity ratio of 0.85. Thermo Fisher Scientific Inc. has a 12-month low of $140.00 and a 12-month high of $214.57. The stock has a market capitalization of $85,170.00, a PE ratio of 36.25, a PEG ratio of 1.72 and a beta of 1.06.
Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The firm had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $5.03 billion. During the same quarter last year, the company posted $2.03 earnings per share. The firm’s revenue was up 13.9% compared to the same quarter last year. analysts predict that Thermo Fisher Scientific Inc. will post 9.36 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Monday, January 15th. Investors of record on Friday, December 15th were issued a dividend of $0.15 per share. The ex-dividend date was Thursday, December 14th. This represents a $0.60 annualized dividend and a dividend yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.19%.
In related news, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the completion of the transaction, the chief executive officer now owns 252,577 shares of the company’s stock, valued at $47,582,981.03. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.49% of the company’s stock.
A number of research analysts have issued reports on the stock. Jefferies Group reaffirmed a “hold” rating and issued a $195.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, September 28th. BTIG Research assumed coverage on shares of Thermo Fisher Scientific in a report on Friday, January 5th. They issued a “buy” rating and a $230.00 price target for the company. Zacks Investment Research cut shares of Thermo Fisher Scientific from a “hold” rating to a “sell” rating in a report on Thursday, January 11th. Goldman Sachs Group assumed coverage on shares of Thermo Fisher Scientific in a report on Tuesday, September 26th. They issued a “buy” rating and a $225.00 price target for the company. Finally, Barclays reaffirmed an “overweight” rating and issued a $215.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Monday, September 25th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and fifteen have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $212.21.
COPYRIGHT VIOLATION WARNING: This story was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://ledgergazette.com/2018/01/19/thermo-fisher-scientific-inc-tmo-holdings-raised-by-tealwood-asset-management-inc.html.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.